Corteva
Corteva's revenue rose 2.9% to $17.4 billion in fiscal 2025. Its net margin was 6.3%, up from 5.4% a year earlier. Free cash flow was $2.8 billion, up 81.8%. It paid out $1.5 billion in dividends and buybacks, 55% of free cash flow. The diluted share count fell 2.1%.
Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Revenue and margins
Net income and earnings per share
From fiscal 2020 to 2025, earnings per share grew 11.9% a year and net income 9.9% a year, as buybacks cut the share count by 9%.
Returns on capital
Cash flow
Payouts and share count
Valuation
Two ways to value Corteva yourself, both starting from its filings: a discounted cash flow model and the price-to-earnings method.
Discounted cash flow (DCF)
A discounted cash flow (DCF) model values a business as the cash it may generate in future, discounted back to today. The starting figures come from Corteva's 10-K (or, for net cash and shares, its latest 10-Q) and the assumptions are yours: start from one of three example scenarios, then change any figure to see what it implies for a share, and how that compares with the last share price.
Value per share on three example scenarios, from Corteva's fiscal 2025 free cash flow of $2.8B, net cash of $1.9B at December 31, 2025 and 681 million diluted shares, from its filings. The scenarios are fitted to Corteva: the base scenario's growth in years 1 to 5 is its revenue growth over the last 3 years, -0.1% a year, kept between 0% and 20%; the cautious and optimistic ones are lower and higher, and growth in years 6 to 10 is halfway to the long-run rate. The base scenario's discount rate is 13%: 11% for a cyclical or higher-risk business (Fertilizers & Agricultural Chemicals), plus 1 point as a smaller company, worth $8.0B, plus 1 point for unsteady results (revenue fell in two of the last five years); the cautious and optimistic ones use a point more and a point less. Select one to load it into the calculator. These are the model's arithmetic on those assumptions, not a forecast or a price target.
- Last close, October 26, 2026
- $11.95
- Value on these assumptions, against the last close
- —
- Cash flows in years 1 to 10, valued today
- —
- Everything after year 10, valued today
- —
- Plus net cash
- —
- Share of value from after year 10
How the value changes with two assumptions
Price-to-earnings (P/E) method
Another common way to value a company is to multiply its earnings per share by a price-to-earnings (P/E) multiple: the number of years of today's earnings an investor pays for a share. A higher multiple usually means investors expect earnings to grow. Choose a multiple, for example from similar companies, to see the value it gives.
Value per share on three example scenarios, from Corteva's earnings per share of $1.52 (over the last four quarters). Each grows earnings for a year at the cash flow scenarios' rates and applies a multiple to next year's earnings: 14.2×, the average of the Materials median and Corteva's own P/E today for the base scenario, 20% less and more for the cautious and optimistic ones. The price is brought back a year at 14%, 13% and 12%. Select one to load it into the calculator. These are the model's arithmetic on those assumptions, not a forecast or a price target.
- Last close, October 26, 2026
- $11.95
- Value at this multiple, against the last close
- —
- Corteva's P/E at the last close
- 7.9×
| Company | Last close | Earnings per share | P/E today |
|---|---|---|---|
| CF IndustriesCF | $120.84 | $13.48 | 9.0× |
| CortevaCTVA | $11.95 | $1.52 | 7.9× |
Balance sheet
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 4,545 | 3,315 | 2,742 | 3,169 | 4,530 |
| Debt incl. finance leases | 1,117 | 1,307 | 2,489 | 2,703 | 2,580 |
| Net debt (negative means net cash) | −3,428 | −2,008 | −253 | −466 | −1,950 |
| Net debt to EBITDA | −0.9x | −0.7x | −0.1x | −0.2x | −0.6x |
| Debt to equity | 0.0x | 0.1x | 0.1x | 0.1x | 0.1x |
| Interest coverage | 79.2x | 19.1x | 5.7x | 6.5x | 10.4x |
| Current ratio | 1.6x | 1.6x | 1.6x | 1.4x | 1.4x |
| Quick ratio | 1.1x | 0.9x | 0.9x | 0.9x | 1.0x |
Insider trades
Over the 12 months between October 27, 2025 and October 26, 2026, no insider bought Corteva shares on the open market, and 1 insider sold $636,213.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Feb 20, 2026 | Brian TitusSee Remarks | Sold | 8,311 | $76.55 | $636,213 | Form 4 |
Piotroski F-score
The F-score counts how many of nine simple tests of profitability, funding and efficiency a company passed in a year (Piotroski, 2000). The more tests passed, the stronger the year: 8 or 9 is strong, 0 to 2 weak. Companies that report no gross profit are scored on the other eight.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Pass |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Pass | Pass | Pass |
| Gross margin rose | Pass | Pass | Pass |
| Revenue rose relative to assets | Fail | Fail | Pass |
| F-score | 5 of 9 | 6 of 9 | 8 of 9 |
| Accruals ratio | −2.4% | −3.0% | −5.5% |
Compare
Put Corteva side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Corteva | FY25 | 2.9% | — | 16.2% | 5.8% | −0.6x | 8 | |
| Mosaic | FY25 | 8.4% | 6.8% | −4.4% | 2.5% | 2.5x | 8 | Compare |
| Nutrien | FY25 | 3.5% | 13.9% | 7.9% | 8.0% | 1.6x | 9 | Compare |
| CF Industries | FY25 | 19.3% | 32.5% | 25.4% | 20.6% | 0.4x | 8 | Compare |
| FMC | FY25 | −18.3% | −47.0% | −3.0% | −19.6% | — | 2 | Compare |
8 years of figures
| Fiscal year | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 14,287 | 13,846 | 14,217 | 15,655 | 17,455 | 17,226 | 16,908 | 17,401 |
| Revenue growth | — | −3.1% | 2.7% | 10.1% | 11.5% | −1.3% | −1.9% | 2.9% |
| Gross profit | 4,339 | 5,271 | 5,710 | 6,435 | 7,019 | 7,306 | 7,379 | 8,229 |
| Research and development | 1,355 | 1,147 | 1,142 | 1,187 | 1,216 | 1,337 | 1,402 | 1,474 |
| Operating income | — | — | — | — | — | — | — | — |
| Net income | −5,065 | −959 | 681 | 1,759 | 1,147 | 735 | 907 | 1,094 |
| Diluted EPS (US$) | −6.76 | −1.28 | 0.91 | 2.37 | 1.58 | 1.03 | 1.30 | 1.60 |
| Diluted shares (millions) | 749 | 750 | 751 | 742 | 724 | 712 | 696 | 681 |
| Cash flow | ||||||||
| Cash from operations | 483 | 1,070 | 2,064 | 2,727 | 872 | 1,769 | 2,145 | 3,406 |
| Capital expenditure | 1,501 | 1,163 | 475 | 573 | 605 | 595 | 597 | 591 |
| Free cash flow | −1,018 | −93 | 1,589 | 2,154 | 267 | 1,174 | 1,548 | 2,815 |
| Dividends paid | 0 | 194 | 388 | 397 | 418 | 439 | 458 | 475 |
| Share buybacks | 0 | 25 | 275 | 950 | 1,000 | 756 | 1,009 | 1,071 |
| Acquisitions | 0 | 10 | 0 | 0 | 0 | 1,456 | 0 | 0 |
| Stock-based compensation | — | — | — | — | — | — | — | — |
| Balance sheet at fiscal year end | ||||||||
| Cash and short-term investments | 2,275 | 1,769 | 3,795 | 4,545 | 3,315 | 2,742 | 3,169 | 4,530 |
| Debt incl. finance leases | 7,938 | 122 | 1,105 | 1,117 | 1,307 | 2,489 | 2,703 | 2,580 |
| Total assets | 108,683 | 42,397 | 42,649 | 42,344 | 42,618 | 42,996 | 40,825 | 42,845 |
| Total liabilities | 33,530 | 17,842 | 17,586 | 16,721 | 17,077 | 17,717 | 16,795 | 18,459 |
| Shareholders' equity | 74,660 | 24,309 | 24,824 | 25,384 | 25,302 | 25,037 | 23,789 | 24,144 |
| Margins and ratios | ||||||||
| Gross margin | 30.4% | 38.1% | 40.2% | 41.1% | 40.2% | 42.4% | 43.6% | 47.3% |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | −35.5% | −6.9% | 4.8% | 11.2% | 6.6% | 4.3% | 5.4% | 6.3% |
| Free cash flow margin | −7.1% | −0.7% | 11.2% | 13.8% | 1.5% | 6.8% | 9.2% | 16.2% |
| Return on capital | — | −0.3% | 3.2% | 8.3% | 5.6% | 4.7% | 4.2% | 5.8% |
| Return on equity | — | −1.9% | 2.8% | 7.0% | 4.5% | 2.9% | 3.7% | 4.6% |
| Return on assets | — | −1.3% | 1.6% | 4.1% | 2.7% | 1.7% | 2.2% | 2.6% |
| Net debt to EBITDA | — | −1.2x | −1.4x | −0.9x | −0.7x | −0.1x | −0.2x | −0.6x |